Cardiology Plus (Jan 2020)

Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy in a patient with prior transcatheter aortic valve replacement

  • Jian-An Wang,
  • Xin-Ping Lin,
  • Ju-Bo Jiang,
  • Xian-Bao Liu,
  • Jun Jiang,
  • Zhao-Xia Pu,
  • Li-Han Wang,
  • Hua-Jun Li,
  • Fei Lv

DOI
https://doi.org/10.4103/cp.cp_12_20
Journal volume & issue
Vol. 5, no. 2
pp. 97 – 100

Abstract

Read online

A 68-year-old man presented with chest distress recurring for the past 10 years. An echocardiogram demonstrated bicuspid aortic valve malformation with severe aortic stenosis and ventricular septal thickness of 22 mm. The patient underwent successful transcatheter aortic valve replacement (TAVR). Six months later, he complained of worsening dyspnea and chest distress (New York Heart Association Class III) on exertion. Besides a functional normal AV prosthesis, the echocardiography indicated the left ventricular outflow tract obstruction peak gradient of 122 mmHg at rest. Alcohol septal ablation was performed as the patient was unable to tolerate morrow procedure. His symptoms were relieved immediately after ablation, and no major cardiovascular events were observed during the 20-month follow-up. In conclusion, among patients with concomitant hypertrophic obstructive cardiomyopathy and severe aortic valvular stenosis, consideration for TAVR and alcohol septal ablation should only be made for patients who are at high surgical risk or cannot tolerate thoracotomy.

Keywords